As a key resource during the COVID-19 pandemic, pharmacists have quickly been acknowledged as crucial contributors to patient care and better health outcomes.

As more people turn to diabetes medication to manage their weight, obesity has become a pressing concern for employers.

We sat down with Ria Westergaard, director of product innovation and a pharmacist who leads Evernorth's Clinical Trials team, to better understand the work her team does and how it improves patient outcomes. 

Gene therapies bring much-needed hope for treating rare conditions, but also concerns, especially around affordability. Learn about strategies plan sponsors can take to address these million-dollar medications.

The ever-evolving complexity of medications billed through the medical benefit requires continuous investment in processes to manage their increasingly high price tag.

The Evernorth Research Institute analyzed aggregated and anonymized data of almost 5 million insured individuals to understand the prevalence of "cardiodiabesity" — a condition which encompasses cardiovascular disease, type 2 diabetes and obesity.